Webinar Overview
Drug-induced liver injury (DILI) or hepatotoxicity has consistently been a leading cause of drug withdrawal from the market over previous decades. While technology has evolved to provide better predictions for DILI risk even in pre-clinical stages, DILI still remains a major concern for drug developers and regulators.
The complexity of DILI further complicates strategies for hepatotoxicity de-risking. Liver toxicity may be acute or chronic, dose-dependent or idiosyncratic, and result in a wide range of clinical representations from hepatic necrosis through hepatocellular hepatitis to different types of cholestasis. How can we differentiate between the different DILI mechanisms, and more importantly, how can we “de-risk” a toxicity with no unified defining criteria?
To address the issue of hepatotoxicity prediction and de-risking, in this webinar, we:
- Present an overview of the complexities of DILI
- Discuss how to build a de-risking plan based on current mechanistic knowledge
- Demonstrate the importance of incorporating hepatotoxicity de-risking in the early stage of drug development for risk management and data-driven decision making
- Identify key risk factors and red flags
- Review the various tools available, including in silico, in vitro, and in vivo, focusing on their application and predictive value
Learn how to apply pre-clinical tools to “liver-proof” your drug.
Webinar Presenters
Ludovico Buti
Senior Research Leader